ZNF680

Across TCGA pan-cancer cohorts, ZNF680 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF680 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF680 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF680 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and LUSC are the cancer types where ZNF680 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
UCEC	DFS	Median	All	0.965	0.631	.016	18	view →
LUSC	OS	Median	III,IV	0.140	0.664	.016	12	view →
READ	DFS	Median	All	0.162	0.720	.019	9	view →
COAD	OS	Median	III,IV	0.140	0.691	.017	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF680–LIHC (OS)

Open the LIHC breakdown →